Status:
COMPLETED
Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy
Lead Sponsor:
Yonsei University
Conditions:
Prostate Tumor
Eligibility:
MALE
19+ years
Phase:
NA
Brief Summary
The investigators conduct a random assignment into either the remimazolam group or the propofol group. Depending on the group assignment, either remimazolam (0.2 mg/kg) or propofol (1.0 mg/kg) is admi...
Eligibility Criteria
Inclusion
- Patients who undergo robot-assisted laparoscopic prostatectomy and who have taken renin-angiotensin system blockers for more than 3 months.
Exclusion
- emergency surgery
- If the subject includes those who cannot read the consent form (e.g. illiterate, foreigners, etc.)
- cognitive dysfunction
- Atrial fibrillation, moderate to severe valvular disease, ejection fraction of 35% or less
- Patients who did not take renin-angiotensin system blockers on the day of surgery
Key Trial Info
Start Date :
November 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2024
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT06093971
Start Date
November 17 2023
End Date
October 22 2024
Last Update
December 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University College of Medicine
Seoul, South Korea